Merck’s $6.7B Terns Deal Shows Big Pharma Is Preparing for Patent Cliffs

Merck has agreed to acquire biotechnology company Terns Pharmaceuticals in a deal valued at approximately $6.7 billion, strengthening its oncology pipeline ahead of the upcoming patent expiry of its blockbuster drug, Keytruda.

The acquisition centres around TERN-701, an experimental treatment for chronic myeloid leukaemia currently in clinical development. The drug has shown promising early results and could become a major revenue driver if approved.

Preparing for the Keytruda Patent Cliff

The strategic motivation behind the deal is clear. Keytruda is one of the world’s best-selling drugs and generates tens of billions in annual revenue for Merck. However, key patent protections begin to expire in 2028, creating a potential revenue gap.

Large pharmaceutical companies often respond to these “patent cliffs” by acquiring late-stage drugs or biotechnology companies with promising pipelines. The Terns acquisition appears to be part of Merck’s broader strategy to replace future lost revenue with new oncology products.

A Wider Industry Trend

This deal is part of a wider trend across the pharmaceutical industry. Many major drugmakers are increasingly acquiring smaller biotech companies rather than relying solely on internal research and development. This approach allows them to access new technologies, pipelines and therapeutic areas more quickly.

Oncology remains the most active area for pharmaceutical acquisitions, with companies investing heavily in targeted therapies, immunotherapies and rare cancer treatments. What This Means for the Industry

The Merck–Terns deal highlights three major trends in pharma:

• Companies are preparing for major patent expiries

• Oncology remains the top investment area

• Big pharma increasingly buys innovation from biotech rather than building it internally

  
  

As patent cliffs approach for several blockbuster drugs across the industry, further acquisitions and licensing deals are likely over the next few years.

Summary

As Merck moves to secure its next generation of oncology treatments, this acquisition underscores the growing importance of strategic biotech partnerships for big pharma to stay ahead in an increasingly competitive, patent‑driven market.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com